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ABSTRACT 
Background/objective: Irisin is suggested to be an exercise beneficial effects mediator. This study 
aimed to examine the effects of the aerobic exercise (AE), resistance exercise (RE), and 
combined exercise (CE) on the plasma levels of irisin and some metabolic and anthropometric 
indices.  
Methods: Sixty overweight women with metabolic syndrome were assigned equally into four 
groups: AE, RE, CE, and control. The study variables were measured before and 24 hours after 
the intervention period.  
Results: None of the study groups showed statistically significant changes in the serum irisin. 
However, muscle mass significantly increased in the RE and CE groups. Also, a significant 
decrease was observed in the body fat percentage in all groups. In addition, compared with the 
control group, the homeostatic model assessment of insulin resistance in the AE (p=0.021), RE 
(p=0.039), and in the CE (p=0.003) groups reduced significantly. According to the analysis of 
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indices’ changes, serum irisin was significantly correlated with the body fat percentage (r=0.532) 
and HOMA-IR (r=0.424).  
Conclusions: The systematic exercise program for 8-weeks did not change circulating irisin and 
no statistically significant difference was observed between the exercise methods. Also, serum 
irisin seemed to be associated with the glycemic status, body fat and weight independent of 
exercise activity. 
Keywords: Metabolic syndrome, irisin, HOMA-IR, exercise program, insulin, aerobic, 
resistance. 
 
INTRODUCTION 
Despite the unquestionable health beneficial effects of regular exercise, little is known about 
underlying molecular pathways that regulate these effects. 1 There are several signal peptides 
termed myokines, which have been introduced in recent years as key regulators. 2 Myokines are 
secreted from skeletal contracting muscles, the largest organ in the human body, and are known 
to have endocrine effects on other organs. Irisin is one of the newest myokines described by 
Boström et al. in 2012. 3 Irisin is an exercise-induced myokine and has been suggested to 
increase energy expenditure through the browning of adipose tissue. 2 It has been suggested that 
the browning process of adipose tissue via irisin may be a body response to the cold environment 
and physical activity. 4 The upregulation of the peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha (PGC-1α), as a transcript activator, due to physical activity enhances 
the expression of fibronectin type III domain-containing protein 5 (FNDC5) gene. FNDC5 gene 
encodes the precursor protein for irisin production. 3 
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Previous research on irisin secretion has shown that muscle tissue plays an important role in 
raising the blood level of irisin following exercise. 5, 6 Serum irisin levels rise and peak 
immediately and last shortly after the exercise session. 7 It has been reported that elevated irisin 
levels in response to exercise may reduce weight in obese individuals and insulin resistance in 
patients with diabetes. 8-10 In addition, serum irisin has been found to have an inverse correlation 
with glucose intolerance. 11 However, it is not clear whether exercise can increase the baseline 
serum irisin. As shown in population studies, high serum irisin levels reduce the risk of BMI 
enhancement and coronary atherosclerosis. 12, 13 Moreover, a short-term increase in serum irisin 
due to exercise is responsible for some beneficial metabolic changes. 14, 15 This becomes more 
complicated when we find that the lipid tissue is responsible for the baseline level of irisin in the 
blood among obese individuals. 16 Furthermore, the serum irisin level is positively correlated with 
higher waist circumference, body fat mass, and unfavorable lipid profile. 17, 18 
Putting aside the conflicting results, physical activity is regularly prescribed in patients with 
different metabolic diseases including diabetes, 1 dyslipidemia and metabolic syndrome (MetS). 
MetS, as a cluster of health-related conditions including glucose intolerance, hypertension, 
dyslipidemia and central obesity, is an overwhelming health problem across the globe. 19 
Regardless of the molecular pathways, regular exercise, especially a program with a combination 
of aerobic and resistance training can improve MetS indices. 20 
To the best of our knowledge, the effects of a variant exercise program on serum irisin using a 
well-controlled clinical trial have not been studied yet. Therefore, this study aimed to examine 
two hypotheses: (i) whether different exercise regimens including aerobic, resistance, and a 
combination of aerobic and resistance, could increase the serum irisin and, (ii) whether changes in 
the serum irisin levels are associated with changes in other metabolic parameters in women with 
MetS. 
MATERIALS and METHODS 
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Participants  
This randomized controlled trial was performed on the basis of the CONSORT 2010 flow 
diagram (Figure 1) to examine the effects of aerobic exercise (AE), resistant exercise (RE), and 
combined exercise (CE) on the levels of plasma irisin, fasting blood sugar (FBS), insulin, insulin 
resistance (HOMA-IR), lipid profile, and body composition in obese women with MetS. The 
primary hypothesis of this study was that a significant change in the irisin level would be 
observed after the exercise program compared to that at the baseline measurements. The second 
hypothesis was that statistically significant changes would be observed in the plasma levels of 
HOMA-IR and lipid profiles. MetS was confirmed when at least three of the following conditions 
were met: abdominal obesity (waist circumference greater than 88 cm in women and 102 in men), 
triglyceride ≥ 150 mg/dL, HDL-cholesterol ≤ 40 mg/dL in men and ≤ 50 mg/dL in women, 
hypertension (systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 85 mmHg), 
and increased FBS (≥ 100 mg/dL) 21. Inclusion criteria for subjects were as follows: having at 
least three diagnostic criteria of MetS, aged between 46 and 60 years and being at the pre-
menopausal period, non-smoker, no history of cancer, no history of cardiovascular and 
musculoskeletal disorders, no use of dietary or ergogenic supplements, and willingness to take 
part in the study. Exclusion criteria were unwillingness to continue with the intervention, missing 
more than 10 percent of the exercise sessions, pregnancy and starting a specific dietary regimen. 
The Ethics Committee affiliated with Shiraz University of Medical Sciences approved the 
research proposal and corroborated its ethical considerations throughout the study (decree code: 
IR.SUMS.REC. 1397.279). 
Study Design  
The study protocol was registered on the Iranian Registry of Clinical Trials (IRCT) under 
registration code of IRCT20180806040721N2. The study was conducted from February to April 
2018 on 60 overweight/obese women with MetS selected from women visiting a public clinic 
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affiliated with Shiraz University of Medical Sciences, Iran. Block randomization with the block 
size of four was used for assigning the subjects into four groups: (I) AE, (II) RE, (III) CE, and 
(IV) control group. Each group consisted of 15 women who were not blind to group assignments 
due to the nature of interventions. However, neither the laboratory staff nor the data collectors or 
the biostatistician were aware of group assignments. The eligible women were contacted by a 
nurse to participate in the study. The women were informed of the study method and objectives 
and were asked to sign the informed consent form before the initiation of the study. They were 
examined by a general practitioner before commencing the study to ensure that the interventions 
would not jeopardize their health condition.  
Intervention: The exercises program 
The control group were advised not to change their physical activity during the study. Also, their 
compliance with the interventions was monitored every other week via phone calls. 
Aerobic exercise (AE) consisted of running on the treadmill (Cosmuse/hp model Saturn ,®  
Germany) three times per week on non-consecutive days. In the group-based training sessions, 
the exercise time was increased gradually from 30 minutes to 60 minutes in each session after two 
weeks. Each 60-minute session consisted of stretching exercises (10 min), treadmill walking and 
stationary cycling (40 min), and balance exercises (10 min). They were allowed to have a 5- to 
10-minute rest during each session. The exercise intensity was based on the maximum heart rate; 
it started at 60% and was gradually elevated to 75% during the exercise. The heart rate was 
monitored using the wristband heart rate monitor. The accuracy of the wristband heart rate 
monitor was approved through comparing the results with those collected via 
electrocardiography. The target heart rate was calculated using the Karvonen formula: (HR 
Target=HR Rest + [(%Desired intensity) × ( HR Max   - HR Rest)]) 22. 
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Resistance training (RE): The exercise techniques were instructed to the women and their 
performance was supervised by professional trainers in group-based training sessions. The 
exercise was performed for 2 sessions per week (each session 60 min) during the first two weeks 
and was increased to 3 sessions on non-consecutive days per week. Similar to the aerobic 
exercise, each resistance session was started with 10 min of stretching exercises followed by 40 
min of strength exercises and 10 min of balance exercises. Strength training consisted of 2 sets of 
10 different exercises, including bench press, seated row, shoulder press, chest press, lateral pull-
down, abdominal crunches, leg press, leg extension, triceps pushdown, and seated bicep curls, for 
upper and lower parts of the body 23. The subjects had 8-10 repetitions for each exercise and 5-10 
min of rest between each set. For the first two weeks of training, the intensity of the exercises was 
60% one repetition maximum (1RM) and was elevated to 75-80% 1RM from the 3rd week on. 
One repetition maximum was calculated based on the Brzycki formula: 1RM = 
 
   ()
(.(. ×  
 ))
 
Combined exercise (CE): This group also participated in group-based training sessions, so that 
they performed both AE and RE simultaneously in one session. The CE group performed exercise 
two sessions a week for the first two weeks and three sessions for the rest of the intervention 
period. Each session was started with 10 min stretching exercises and 20 min walking on a 
treadmill, followed by 5 min rest and one set of strength training, consisting of 10 different 
exercises similar to the RE exercise program. The sessions were ended with 10 min balance 
exercises. The intensities of the aerobic and strength exercises were gradually increased 
according to the AE and RE protocols, respectively. 
Nutrition and supplements 
Dietary intake was evaluated using a 24-hour dietary recall before and after the intervention. The 
subjects were also asked not to change their dietary habits during the intervention. They were 
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contacted every other week by a nutritionist to ensure that no dietary changes occurred. A 24-
hour dietary recall questionnaire was used to collect data on dietary energy and macronutrient 
content. Data were entered into Nutritionist IV software (First Databank® Inc., Hearst Corp., San 
Bruno, CA) for analysis.  
Measurement 
Demographic data were collected before the intervention. The anthropometric parameters, 
including body weight, height circumference, waist circumference, and hip circumference, were 
measured in the morning without shoes and with minimal clothing according to the WHO 
guideline. 24 The body mass index (BMI) and waist-to-hip ratio (WHR) were calculated. Body 
composition parameters, including body fat percentage (%BF) and skeletal muscle mass (SMM), 
were measured using the bioelectric impedance analysis (InBody 720; BioSpace®, Co., Korea) 
with patients in the standing position, in the normal hydration status, and no vigorous exercise 
session for at least 6 hours before the measurement. Blood pressure was measured in the seated 
position after 5 min rest, and the average of the two consecutive measurements was recorded. 
Before the intervention, 5 mL of venous blood was taken from each participant in the morning 
after 12 hours of fasting. The samples were incubated for 15 min in the room temperature for 
clotting and then centrifuged for 10 min in 4000 rpm to separate serum. The serum was frozen at 
–70 °C until the time of laboratory analysis. In the second stage, the blood samples were collected 
24 hours after the last exercise bout of the eighth week of the intervention and all processes on 
blood samples were repeated. 
Fasting serum glucose, total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglyceride 
were measured by commercial kits (Pars Azmoon®, Tehran, Iran) and using the photometric and 
enzymatic methods and an autoanalyzer (Biotecnica instrument®, Rome, Italy). The serum fasting 
insulin and serum irisin levels were assessed by the enzyme-linked immunosorbent assay 
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(ELISA) method and using the human insulin kit (ZellBio®, Ulm, Germany) and human irisin kit 
(Phoenix Pharmaceuticals®, Burlingame, USA). HOMA-IR was calculated using the following 
formula: HOMA-IR=[fasting glucose (mg/dL) × fasting insulin (mU/L)/405]. An overview of the 
study protocol is presented in figure 2. 
Statistical analysis 
The sample size was calculated to detect at least a 1.5 ng/ml (SD=1.3) difference between the 
groups in terms of the plasma irisin level after the interventions. In addition, the alpha and power 
were set at 0.05 and 80%, respectively. Accordingly, the sample size was estimated as 15 
participants per group. 25, 26 The extracted data were entered into the SPSS software for analysis. 
The Kolmogorov-Smirnov test was used to assess the normal distribution of data. The baseline 
status of the individuals was compared using the ANOVA test. The paired sample t-test and the 
Mann-Whitney U test were used to compare differences in the means of parametric and non-
parametric variables, respectively, before and after the intervention period. The effectiveness of 
exercise programs was examined through comparing the mean difference of changes in each 
variable using the ANCOVA test, adjusted for the baseline body weight as a covariate, followed 
by the Bonferroni post hoc test. The significance level was set as p<0.05, and the data analysis 
was performed using the IBM SPSS Statistics 25 (Armonk, NY: IBM Corp). 
RESULTS 
Participant characteristics 
The data were collected from 54 women (control group: n=15; AE group: n=13; RE group: n=13; 
CE group: n=13). Six women (AE group: n=2; RE group: n=2; CE group: n=2) were excluded 
because of failure to complete more than 90% of the exercise sessions or traveling (full analysis 
set; Figure 1). The participants’ mean age was 53.47 (SD=6.53) years, and 40 (60%) participants 
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had minimal or no formal education. Age and education showed no statistically significant 
difference between the study groups. 
Baseline in terms of anthropometric, dietary recall, and biochemical characteristics 
As shown in Table 1, except body weight, no statistically significant differences were observed 
between the groups at the baseline in terms of anthropometric and biochemical characteristics. 
About 23% of the participants were diagnosed with diabetes. According to the dietary recall, as 
summarized in Table 2, energy, macronutrient, and fiber intakes at the end of the study had no 
differences significantly with those at the baseline.  
Intergroup comparison 
After the interventions, a significant reduction was observed in the women’s weight, body fat 
percentage, and BMI in the AE and CE groups (Table 3). In addition, resistance and combined 
exercise groups gained significant skeletal muscle mass (1.67 Kg and 1.33 Kg, respectively) after 
the exercise period. All the intervention groups exhibited improvements in the insulin resistance 
index compared to the baseline. However, the RE group did not reach a significant level. Fasting 
serum triglyceride levels in the intervention groups declined significantly. However, changes in 
other lipid profiles were not significant, except for the total cholesterol in the AE (p=0.033) and 
CE (p=0.022) groups, in which a decline from the baseline values was observed. The serum level 
of irisin after eight weeks of the intervention did not change significantly in the AE (p=0.221), 
RE (p=0.152) and CE (p=0.303) groups from the baseline measurements (7% increase, 3% 
decrease, and 3% increase, respectively). 
Intragroup comparison 
Figure 3 shows changes in each parameter and the intragroup comparisons after the interventions 
in the study groups. Body weight decreased significantly in the AE and CE groups in comparison 
with that of the control group (p=0.026 and p=0.019, respectively). In addition, body fat 
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percentage decreased significantly in all intervention groups. However, only the RE and CE 
groups developed greater skeletal muscle masses. 
On the other hand, irrespective of the type of exercise, the interventions induced a significant 
reduction in fasting glucose (p=0.013), HOMA-IR (p< 0.001), and triglyceride (p=0.020) in 
comparison to those of the control group. At the eighth week of follow-up, comparing the 
changes in serum irisin showed no statistically significant differences between the groups 
(p=0.117). 
Table 4 represents correlations between the changes in the irisin level and other variables. The 
changes in serum irisin were statistically correlated with the changes in the body weight (r=-
0.357, p=0.01), body fat percentage (r=0.532, p=0.01), and HOMA-IR (r=0.424, p=0.02). Also, 
Irisin was inversely correlated with cholesterol (r= -0.637, p=0.01) in the AE group. 
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DISCUSSION 
This study aimed to compare the effects of eight weeks of aerobic, resistance, and a combination 
of aerobic and resistance exercises on the serum levels of irisin, glycemic indices, and lipid 
profiles in women with MetS. The main finding of this randomized controlled trial was that 
serum irisin levels did not change after exercise compared with those before the intervention. In 
addition, none of the AE, RE or CE groups exhibited a different pattern of irisin secretion due to 
the exercise interventions compared with that of the control group. The effectiveness of the 
exercise regimens was confirmed based on the significant reductions of body fat in the AE, RE, 
and CE groups and greater skeletal muscle masses in the RE and CE groups.  
Several studies have explored the effects of different exercise regimens on serum irisin. 
Nonetheless, their results have not been consistent enough to warrant a firm conclusion. This 
study found no significant change in circulating irisin due to the exercise intervention, but Huh et 
al. 25 showed that regardless of the participants’ age, fitness level, or health status, different 
exercise regimens, including high-intensity swimming, treadmill, and resistance exercise, 
increased the level of circulating irisin. Similarly, Daskalopoulou et al. 27 showed that three 
different exercise protocols significantly increased serum irisin, especially after a maximal 
exercise workload. These discrepant results could be due to differences in study designs. Huh et 
al. measured serum irisin during and minutes after an acute exercise session, but the subjects in 
the present study were evaluated after several weeks of training and in the resting state. Norheim 
et al. reported that the plasma levels of irisin increased right after 45 minutes of ergometer 
cycling and dropped 2 hours post exercise. Since the production of irisin is dependent on PGC-1α 
activity and FNDC5 transcription, during acute exercise, the sharp increase in serum irisin could 
be due to FNDC5 mRNA translation rather than FNDC5 transcription. 4 The study of Norheim et 
al. showed that PGC-1α transcription and FNDC5 mRNA expression increased significantly after 
12 weeks of systematic exercise, but these increases did not translate to higher concentrations of 
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serum irisin, which was consistent with our results. Likewise, Hecksteden et al. 28 reported that 26 
weeks of aerobic or strength training did not induce an increase in irisin production while it 
significantly improved maximal performance. 
In addition to acute or chronic exercise intervention, patients’ anthropometric and health status 
may also affect the results. In this study, the subjects were overweight/obese and were diagnosed 
with MetS. Similarly, the participants in Norheim et al.’s study were obese and prediabetic 
volunteers, but the Pekkala1 et al.’s 29 study focused on healthy man, and their findings did not 
confirm the effects of AE, RE, and CE in inducing PGC-1α and FNDC5 expression or irisin in 
healthy men. Timmons et al. (2012) studied the effects of endurance and resistance exercise on 
205 healthy individuals and those with type II diabetes for 6 weeks. The results showed a greater 
expression of fibronectin type III domain-containing protein 5 (FNDC5) in the intervention group 
compared to that of the control group.5 
Recently, Osella et al. 30 evaluated the effects of different diets on the serum irisin concentration 
and found that vegetable proteins and saturated fatty acids were positively associated with serum 
irisin. Unlike the studies reviewed above, the current study used a dietary regimen based on the 
pre-intervention dietary intake to adjust the effect of dietary components on serum irisin. 
As expected, exercise interventions induced a positive change in glycemic indices, and the 
change was more significant in the CE group. Our results were similar to those of a previous 
study that evaluated the efficacy of different exercise regimens on serum omentin-1 in diabetic 
women. 20 The Pearson correlation test showed that changes in the HOMA-IR, body weight and 
body fat percentage were correlated positively with serum irisin in all participants. A positive 
relationship between serum irisin and metabolic disorders, such as obesity, diabetes, and 
cardiovascular diseases, has been reported in previous studies. 31, 32 Stengel et al. 33 showed that 
obese patients had a higher level of circulating irisin than normal-weight subjects. In addition, 
serum irisin was positively correlated with fat mass and insulin resistance. Our study showed that 
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a reduction in insulin resistance or body fat percentage was associated with lower serum irisin. 
Contrariwise, Crujeiras et al. 34 reported that the circulating irisin increased proportionally to the 
weight regain after that patients underwent a calorie-restricted weight reduction diet. 
 There are two hypotheses to explain the underlying mechanism behind the association of serum 
irisin and weight gain. In the first hypothesis, an increase in serum irisin is an adaptive response 
to weight gain and an increase in body fat. In recent years, the interaction between adipose tissue 
and muscle mass has been emphasized as it plays an important role in regulating body weight and 
improving metabolic risk factors. 35 Accordingly, the conversion of white fat tissue to brown 
adipose tissue can increase thermogenesis and energy consumption and, eventually, lead to 
weight loss through myokine irisin. 8 Irisin stimulates the expression and activity of uncoupling 
protein1 (UCP1) and causes the browning of the white adipose tissue. Therefore, it increases 
thermogenesis and total energy expenditure, which, in turn, can reduce obesity. 36, 37 This 
hypothesis was supported by the results of an animal study, in which irisin improveed 
hyperinsulinemia and glucose tolerance in mice with a high-fat diet. 38 In the second hypothesis, 
an increase in serum irisin in adiposity suggests potential irisin resistance. Irisin is supposed to 
improve UCP1 production and promote the browning of white adipose tissues. However, it is 
contradictory that normal weight or anorexic patients have lower levels of circulating irisin than 
obese individuals. While adipose tissue itself secretes irisin, an increase in the body fat and irisin 
secretion does not lead to expected beneficial effects; for instance, it may lead to leptin resistance. 
39
 Leptin is an adipocyte hormone secreted in response to fat deposits and influences the central 
nervous system to suppress the appetite. Despite the anorexigenic effects of leptin and its high 
level in adiposity, obese patients often do not experience reduced appetite. 40 
The results of this study also showed a significant reduction of fasting triglyceride in all groups 
and total cholesterol in the CE group compared to those of the control group. Nonetheless, no 
significant correlation was found between the changes in the lipid profile and serum irisin. 
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Previous studies have shown a positive correlation between lipid profile and irisin concentration 
in adolescents and adults. 41, 42 Contrary to recent studies that used a cross-sectional design, in the 
present study, we conducted a randomized control trial to examine the correlation between the 
changes in irisin concentration and serum lipids. To the best of our knowledge, no other RCTs 
have investigated the relationship between irisin and lipid profile. Also, it must be added that 
changes in total cholesterol or triglycerides and irisin level were independent. 
Study strengths and limitations 
As a limitation, the inclusion of the expression of FND5 gene in skeletal muscle and fat mass 
could reveal the source of circulating irisin in the body. The process of evaluating the dietary 
intake before the intervention and using a dietary regimen based on the pre-intervention intake 
improved the quality of data collection and can be considered a strength of this study. Lastly, we 
recruited women aged 46-60 years that may influence the generalizability of our results to the 
whole population, so our results should be interpreted with caution when other age groups are 
considered.  
Conclusions 
All exercise groups experienced a significant positive change in anthropometric indices after 
eight weeks of training. In addition, fasting serum glucose and insulin resistance index decreased 
in the exercise groups in comparison with those of the control group. Despite no significant 
changes in serum irisin in the study groups, the changes in circulating irisin were positively 
correlated with the changes in the body weight, body fat percentage and HOMA-IR. Aerobic, 
resistance, and combined exercises reduced serum triglyceride. Also, a combination of aerobic 
and resistance exercises effectively reduced LDL-cholesterol. Finally, no significant changes 
were observed in systolic and diastolic blood pressure after the interventions. Different exercise 
regimens did not lead to different results, but combined exercises had more beneficial effects on 
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MetS risk factors. The contradictory results on the effect of exercise in serum irisin levels 
highlight the need for larger-scale RCTs on healthy and non-healthy participants. 
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FIGURE LEGENDS 
 
Figure 1 shows the study process using the CONSORT flow diagram. 
 
Figure 2 demonstrates an overview of the study protocol. 
Figure 3 illustrates the comparison of changes in anthropometric and biochemical indices between the groups.   
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TABLES 
 
Table 1. The baseline characteristics of the women in the groups 
 
Characteristic 
 
Control (n=15) 
Mean ± SD 
Aerobic (n=15) 
Mean ± SD 
Resistance (n=15) 
Mean ± SD 
Combination (n=15) 
Mean ± SD 
P-value* 
 
Height, cm 
 
157.69+8.25 160.00+10.29 
 
159.08+7.39 
 
156.83+7.82 
 
0.802 
Weight, kg 
 
75.61+9.36 73.25+12.28 74.75+11.68 76.83+8.96 0.036 
BMI, kg.cm2 30.41+3.83 28.61+3.46 29.54+2.95 31.23+3.40 0.051 
Body fat, % 
 
35.15+7.77 34.86 +4.15 35.40+9.95 33.84+7.09 0. 239 
Muscle, Kg 
 
39.07+8.41 42.83+11.76 41.83+7.76 42.08+6.84 0.775 
SBP, mmHg 133.08 + 11.12 136.40 + 15.21 131.17 + 9.68 131.68 + 11.47 0.184 
DBP mmHg 87.31 + 9.14 91.02 + 10.11 93.55 + 8.99 89.21 + 10.19 0.323 
FBS, mg. dL 
 
119.07+8.94 128.91+31.65 115.50+12.76 130.66+9.49 0.186 
Insulin, μIU . mL 10.15+1.60 11.57+1.04 10.58+1.55 10.72+1.38 0.894 
HOMA-IR 2.98+0.35 3.37+0.49 3.02+0.65 3.46+0.48 0.604 
TG, mg/dl 160.53+11.70 154.41+12.08 155.41+11.27 155.41+12.68 0.567 
LDL, mg/dl 136.61+12.37 131.58+11.96 129.58+11.98 122.41+11.03 0.098 
HDL, mg/dl 51.84+9.59 51.91+9.26 58.16+13.24 47.25+8.40 0.092 
Chol, mg/dl 152.23+8.47 161.25+10.12 169.25+14.55 153.41+13.05 0.531 
Irisin, ng/mL 
 
9.14±1.32 8.81±1.07 9.42±0.81 8.64±0.98 0.304 
Values are presented as mean ± standard deviation. 
BMI: Body mass index; FBS: Fasting blood sugar; HOMIIR: Homeostatic Model Assessment for Insulin Resistance; HDL: High-
Density Lipoprotein; LDL: Low-Density Lipoprotein; TG: Triglyceride; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure. 
*Analysis of variance (ANOVA) 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Table 2. Dietary intake at baseline and at the end of the interventions in the groups 
Marker Control Aerobic Resistance Combination 
Pre Post p-
value1 
Pre Post p-
value1 
Pre Post p-
value1 
Pre Post p-
value1 
Energy (kcal) 2245 ± 
183 
2298 
± 93 
0.651 2214 
± 209 
2301 
± 216 
0.391 2188 
± 119 
2243± 
232 
0.083 2147 
± 154 
2287 
± 127 
0.411 
Protein (g) 84.74 ± 
11.9 
87.31 
± 9.3 
0.401 81.91 
± 17.5 
82.66 
± 13.3 
0.683 79.92 
± 10.1 
82.47 
± 8.1 
0.432 85.80 
± 9.3 
85.66 
± 12 
0.762 
Total fat (g) 67.35 ± 
8.2 
66.34 
± 9.2 
0.514 65.43 
± 8.5 
62.88 
± 10.1 
0.184 67.58 
± 5.9 
64.19 
± 5.5 
0.214 68.22 
± 11.6 
67.08 
± 7.5 
0.452 
Saturated fat (g) 14.2 ± 
3.1 
12.9 ± 
5.2 
0.213 19.06 
± 6.9 
18.74 
± 8.3 
0.444 16.09 
± 4.4 
16.24 
± 5.2 
0.782 15.4 ± 
6.8 
15.9 ± 
4.4 
0.691 
Monounsaturated 
fat (g) 
26.18 ± 
6.5 
29.03 
± 5.3 
0.153 23.57 
± 6.7 
24.10 
± 8.3 
0.383 26.26 
± 11.3 
27.88 
± 10.6 
0.611 27.44 
± 12.7 
26.85 
± 10.8 
0.473 
Polyunsaturated 
fat (g) 
26.96 ± 
7.0 
24.42 
± 8.2 
0.282 22.81 
± 9.1 
20.04 
± 7.2 
0.172 25.23 
± 9.1 
20.07 
± 6.0 
0.072 25.38 
± 7.4 
24.33 
± 8.8 
0.492 
Carbohydrate (g) 324.96 ± 
35.0 
337.94 
± 43.2 
0.424 346.12 
± 61.2 
351.11 
± 
38.29 
0.272 315.02 
± 59.8 
333.85 
± 41.1 
0.063 297.45 
± 58.5 
335.16 
± 48.3 
0.051 
Dietary fiber (g) 19.0 ± 70 19.3 ± 
50 
0.491 15.3 ± 
40 
16.10 0.141 15.8 ± 
61 
16.20 0.333 17.1 ± 
40 
17.90 0.361 
1
 p-value from the paired sample t-test comparing pre- and post-intervention dietary intakes in each group 
 
 
  
Table 3. Laboratory values and anthropometric measures in the groups at baseline and after 8 weeks of the interventions 
 
Values are presented as mean± standard deviation. 
BMI: Body mass index; FBS: Fasting blood sugar; HOMIIR: Homeostatic Model Assessment for Insulin Resistance; HDL: High-Density Lipoprotein; LDL: Low-Density Lipoprotein; TG: 
Triglyceride; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure. 
Paired sample t-test is based on the analysis of variance, comparing the groups for exact changes (pre- and post-intervention measures); P<0.05 for all comparisons.  
1Paired sample t-test 
2 Based on the ANCOVA for comparing the groups (pre- and post-intervention measures). 
Marker 
 
Control (n=15) 
 
 
Aerobic (n=13) 
 
Resistance (n=13) 
 
 
Combination (n=13) 
 
P 
Value
2
 
Pre Post P 
value
1
 
Pre Post P 
value
1
 
Pre Post P 
value
1
 
Pre Post P 
value
1
 
Weight 
(Kg) 
 
9.36+75.61 9.50+75.84 0.193 12.28+73.25 6.91+71.73 0.031 11.68+74.75 9.74+74.21 0.112 8.96+76.83 9.09+74.02 0.011 0.001 
BMI 
(kg/cm2) 
3.83+30.41 3.85+30.51 0.182 3.46+28.61 3.61+28.01 0.033 2.95+29.54 2.98+29.33 0.104 3.40+31.23 3.04+30.08 0.014 0.001 
Body fat 
(%) 
7.77+35.15 8.06+34.92 0.642 4.15+34.86  5.38+30.82  0.014 9.95+35.40 9.46+33.93 0.083 7.09+33.84 8.26+31.50 0.013 0.011 
Muscle  
(Kg) 
8.41+39.07 7.72+39.15 0.101 11.76+42.83 10.70+43.16 0.102 7.76+41.83 10.75+43.50 0.012 6.84+42.08 8.69+43.41 0.033 0.013 
SBP 
(mmHg) 
+ 133.08 
11.12 
135.12 + 
11.09 
0.893  +136.40 
15.21 
131.22 + 
10.30 
0.214  +131.17 
9.68 
131.78 + 
13.59 
0.781 131.68 + 
11.47 
127.65 + 
10.05 
0.141 0.234 
DBP 
(mmHg) 
9.14 +87.31  88.06 + 7.5 0.452  +91.02 
10.11 
88.50 + 6.48 0.191 8.99 +93.55  90.04 + 
10.10 
0.243 89.21 + 
10.19 
86.87 + 8.92 0.172 0.411 
Glucose 
(mg/dL) 
8.94+119.07 9.05+122.38 0.102 31.6+128.91
5 
28.1+105.08
3 
0.011 12.7+115.50
6 
12.9+113.25
6 
0.111 9.49+130.66 9.93+111.14 0.022 0.010 
Insulin 
(μIU/mL) 
1.60+10.15 1.61+9.98 0.283 1.04+11.57 1.09+10.50 0.084 1.55+10.58 1.52+9.32  0.042 1.38+10.72 1.62+8.45 0.011 0.007 
HOMA-IR 0.35+2.98 0.54+3.01 0.451 0.49+3.37 0.51+2.72 0.035 0.65+3.02 0.64+2.60 0.050 0.48+3.46 0.55+2.31 0.001 0.001 
TG 
(mg/dL) 
11.7+160.53
0 
13.4+160.00
4 
0.593 12.0+154.41
8 
12.6+140.75
7 
0.011 11.2+155.41
7 
10.9+148.66
4 
0.022 12.6+155.41
8 
8.33+142.75 0.011 0.020 
LDL  
(mg/dL) 
12.3+136.61
7 
11.7+137.30
5 
0.121 11.9+131.58
6 
12.7+129.50
4 
0.232 11.9+129.58
8 
12.0+126.33
4 
0.173 11.0+122.41
3 
11.2+117.25
9 
0.061 0.060 
HDL 
(mg/dL) 
9.59+51.84 10.97+52.00 0.781 9.26+51.91 9.03+51.08 0.222 13.24+58.16 14.07+58.83 0.121 8.40+47.25 8.45+50.08 0.050 0.264 
Cholesterol 
(mg/dL) 
8.47+152.23 9.85+151.11 0.762 10.1+161.25
2 
9.12+157.00 0.033 14.5+169.25
5 
12.8+167.33
5 
0.101 13.0+153.41
5 
13.2+147.83
0 
0.022 0.284 
Irisin 
(ng/mL) 
9.14±1.32 9.02±1.33 0.249 8.81±1.07 9.04 ±1.15 0.221 9.42±0.81 9.31±0.97 0.152 8.64±0.98 8.78 ±1.33 0.303 0.117  
  
 
 
Table 4. Correlations between the variables 
Group: Irisin/ 
Markers 
Weig
ht 
BMI Glucose Insulin HOMI-IR Body fat Muscle HDL LDL TG Cholesterol 
All: Irisin -
0.357
* 
0.307 0.381 0.319 0.424* 0.532* -0.191 -0.064 0.089 0.266 0.178 
Combination: Irisin 0.073 0.057 0.022 0.558 0.570 0.370 0.095 0.100 0.159 -0.413 0.066 
Resistance: Irisin -0.548 -0.535 0.058 -0.423 -0.308 0.016 0.326 -0.229 -.0551 -0.111 -0.637* 
Aerobic: Irisin 0.208 0.201 -0.243 0.247 0.044 0.076 -0.286 0.172 0.447 -0.343 0.137 
 
BMI: Body mass index; HOMIIR: Homeostatic Model Assessment for Insulin Resistance; HDL: High-Density Lipoprotein; LDL: Low-Density Lipoprotein; TG: Triglyceride. 
*indicates that the correlation is statistically significant at the 0.05 level (2-tailed). 
  
Figure 1: Study flow diagram  
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Figure 2: An overview of study protocol 
 
 
 
 
 
 
 
  
  
Figure 3. Comparison of changes in anthropometric and biochemical indices between the groups.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*: Significant difference in comparison with the control group (p<0.05) 
&: Significant difference in comparison with the AE group (p<0.05) 
#: Significant difference in comparison with the RE group (p<0.05). 
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